Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 5232 results
Faron expands development strategy for novel immunotherapy drug candidate, Clevegen
Faron Pharmaceuticals has expanded the development strategy for Clevegen, its novel cancer immunotherapy drug candidate.
Drug Research > Drug Discovery & Development > News
Serial BioPharma Entrepreneurial Team launches drug development firm Arrivo BioVentures
Serial BioPharma Entrepreneurial Team has launched Arrivo BioVentures, a drug development company, with $49m in committed funding.
Drug Research > Drug Discovery & Development > News
Allied-Bristol Life Sciences completes ABLS II drug candidate feasibility programme
Allied-Bristol Life Sciences (ABLS), its partnership with Bristol-Myers Squibb Company (BMS), has completed the drug candidate feasibility programme at ABLS II, LLC (ABLS II), and approved up to $15m to fund further development of the lead optimisation programme.
Drug Research > Drug Discovery & Development > News
Redx Pharma reaches pre-clinical proof of concept stage with oncology lead
Redx Pharma has reached pre-clinical proof of concept stage with an oncology lead that has the potential to treat leukaemia and other blood cancers.
Drug Research > Drug Discovery & Development > News
Boehringer Ingelheim, BioMed X start project to identify new treatment approaches for psychiatric diseases
By PBR Staff Writer
Boehringer Ingelheim and BioMed X have started a new project to identify and develop novel treatment approaches for psychiatric diseases.
Drug Research > Drug Discovery & Development > News
Avalon Ventures, COI form PDI Therapeutics to develop novel immune-oncology therapies
By PBR Staff Writer
Avalon Ventures and COI Pharmaceuticals have established PDI Therapeutics to develop novel immune-oncology therapies.
Drug Research > Drug Discovery & Development > News
Acorda to stop Plumiaz development to treat epilepsy seizure clusters
By PBR Staff Writer
Acorda Therapeutics said it will stop the development of its Plumiaz (diazepam) Nasal Spray for the treatment of epilepsy seizure clusters due to disappointing data from ongoing clinical trials.
Drug Research > Drug Discovery & Development > News
Amgen researchers discover gene variation that lowers heart attack risk
By PBR Staff Writer
Researchers from Amgen's deCODE genetics subsidiary have discovered a rare genetic variation that reduces cholesterol levels and heart attack risk in some people.
Drug Research > Drug Discovery & Development > News
Mitochon Pharmaceuticals raises $1.6m for clinical stage development
Mitochon Pharmaceuticals has completed its second year of funding with a total investment of $1.6m.
Drug Research > Drug Discovery & Development > News
Catalyst Pharmaceuticals announces 30% reduction in workforce
Catalyst Pharmaceuticals, which is focused on developing and commercializing new therapies for people with rare debilitating diseases, is reducing its workforce by approximately 30%.
Drug Research > Drug Discovery & Development > News
Agios, Celgene agree to establish metabolic immuno-oncology alliance
By CBR Staff Writer
Agios Pharmaceuticals and Celgene have signed an agreement to establish a new global collaboration focused on metabolic immuno-oncology.
Drug Research > Drug Discovery & Development > News
Pfizer to buy Anacor Pharmaceuticals in $5.2bn deal
By PBR Staff Writer
Pfizer has agreed to acquire Anacor Pharmaceuticals in a transaction valued at about $5.2bn.
Drug Research > Drug Discovery & Development > News
Five Prime advances FPA008 into phase 2 dose expansion in PVNS patients
Five Prime Therapeutics has advanced FPA008 into the Phase 2 dose expansion portion of the ongoing Phase 1/2 trial in PVNS.
Drug Research > Drug Discovery & Development > News
Aegerion reaches preliminary agreements in principle with DOJ and SEC over ongoing investigations
Aegerion Pharmaceuticals has reached preliminary agreements in principle with the Department of Justice (DOJ) and the staff of the Securities and Exchange Commission (SEC) regarding a settlement of the ongoing investigations by these agencies into the Company's sales activities and disclosures related to JUXTAPID (lomitapide) capsules ("JUXTAPID").
Drug Research > Drug Discovery & Development > News
Tetraphase Pharmaceuticals offers update on eravacycline regulatory and development status
Tetraphase Pharmaceuticals has received guidance from the U.S. Food and Drug Administration (FDA) regarding the regulatory path of the Company's lead candidate, eravacycline, an antibiotic with potent activity against drug-resistant bacteria, including MDR pathogens highlighted as urgent public health threats by the CDC.
Drug Research > Drug Discovery & Development > News

PBR Supplier Recommendations

LABORATORIOS INIBSA - Pharmaceutical Contract Manufacturing Company
LABORATORIOS INIBSA is a pharmaceutical contract manufacturing company. We have more than 60 years' experience and belong to the INIBSA GROUP. INIBISA supplies products and services to Biotools, Inibsa Dental and Inibsa Hospital, as well as other pharmaceutical companies through our contract manufacturing division. From our facilities in Lliçà de Vall, 20km from Barcelona LABORATORIOS INIBSA currently supplies more than 50 countries worldwide.... Drug Research > Drug Discovery & Development > Suppliers
Chemoswed - Suppliers of Active Pharmaceutical Ingredients
Chemoswed is the reliable Swedish custom synthesis specialist, supplying active ingredients since 1944. With a background in Pharmacia, Chemoswed is since 1996 an independent entity within the DuPont group, offering cost-effective, turn-key solutions to API needs worldwide.We have established unparalleled experience and technology, enabling efficient development and production of quality active pharmaceutical ingredients in quantities from 100 grams to 50 tons.... Drug Research > Drug Discovery & Development > Suppliers
Novo Nordisk Pharmatech A/S - Insulin Human and Benzalkonium Chloride Products
Novo Nordisk Pharmatech A/S is a Novo Nordisk company that specialises in the supply of ingredients for the biopharmaceutical and pharmaceutical industries, such as insulin human for cell culture media and cGMP manufactured quaternary ammonium compounds (usually referred to as quats) such as benzalkonium chloride, cetrimide and cetrimonium bromide.... Drug Research > Drug Discovery & Development > Suppliers
Biovian - cGMP Contract Manufacturing of Biopharmaceuticals
Biovian is a dynamic and effective new generation one-stop-shop CMO in cGMP contract manufacturing of biopharmaceuticals. Biovian's services cover the full range from antigen isolation, expression, vector construction, cell line cultivation, cGMP protein purification to product fill and finish.... Drug Research > Drug Discovery & Development > Suppliers
Tosoh Bioscience - Your Specialist in Separation
Tosoh Bioscience is an acknowledged global leader in the field of liquid chromatography with a strong focus on bioseparations. We offer solutions for research, drug discovery, clinical chemistry, environmental analysis, manufacturing and other industrial applications. ... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

1.5 Specific dsDNA Quantification UV/VIS-based cDrop™ Method vs Picogreen® Fluorescent Assay By Trinean
Precise quantification and normalization of isolated genomic DNA is critical for advanced molecular testing in life science research and molecular diagnostics. UV-Vis based quantification has long been the method of choice, mainly because of its convenience. However, determining the DNA concentration based on the absorbance at 260nm suffers from interference of components such as RNA, proteins and phenols. Alternative methods, such as the PicoGreen® based Quant-iT™ assay, based on fluorescence enhancement upon binding with dsDNA have been developed to address this issue.... Drug Research > Drug Discovery & Development > White Papers 1.3 Micro-volume Protein Quantification using the DropSense96 Droplet Plate Reader By Trinean
The measurement of protein concentration in aqueous samples is an important assay in biochemistry research and protein production facilities. Spectrophotometric protein quantification assays are commonly used methods to rapidly determine the concentration of a protein. They utilize the direct UV absorbance of the protein at 280nm in combination with its extinction coefficient or an indirect dye-based methods like BCA, Lowry and Bradford assays.... Drug Research > Drug Discovery & Development > White Papers 1.2 DropSense96 and its DropPlates, a Versatile Tool for Nucleic Acid and Protein Droplet Quantification By Trinean
As the demand for molecular tests increases, automated systems for biomolecule isolation and sample analysis are becoming popular. These facilitate integration of the complete molecular test in a full automatic set-up with liquid robots and bar-coded sample tracking resulting in a significant higher throughput while minimizing tedious manual repetitive tasks. The Trinean technology is a unique combination of the DropSense96 droplet plate reader, the 96well DropPlate microfuidic consumables and the DropQuant analytical software enabling direct quantification of small biomolecule samples in these high throughput, automated workflow.... Drug Research > Drug Discovery & Development > White Papers 1.14 Droplet UV/VIS Quantification of Native Proteins in Biopharmaceutical Processing By Trinean
Biopharmaceuticals are mainly produced by microbial fermentation or in animal cell cultures. As a consequence, a cascade of procedures including purification and characterization are required throughout the processing chain to obtain the protein at the desired level of purity and potency. Within these processes, quantification of the protein of interest is mandatory at critical steps to maintain confidence in the processing results and fidelity in the end product.... Drug Research > Drug Discovery & Development > White Papers 1.20 Quantification of His-tagged IgG antibodies after IMAC Ni-column purification By Trinean
Trinean introduces a new cDrop™ application suited for the quantification (OD280) of IgG antibodies and derivatives like Fab fragments during purification by IMAC Ni-columns using imidazole-containing buffers.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 5232 results